Celgene Says FDA Approves Revlimid in Combination with Rituximab for Lymphoma
May 28 2019 - 1:10PM
Dow Jones News
By Michael Dabaie
Celgene Corp. (CELG) said the U.S. Food and Drug Administration
(FDA) approved Revlimid in combination with a rituximab product for
the treatment of adult patients with previously treated follicular
lymphoma or marginal zone lymphoma.
Celgene said this is the first FDA-approved combination
treatment regimen for patients with these indolent forms of
non-Hodgkin's lymphoma that doesn't include chemotherapy.
Approval was based on a Phase 3 study which showed the
combination significantly improved median progression-free survival
versus rituximab monotherapy, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 28, 2019 12:55 ET (16:55 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024